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Abstract 1 
Reovirus type 3 Dearing (reovirus) is a tumour-selective oncolytic virus currently under 2 
evaluation in clinical trials. Here, we report that the therapeutic efficacy of reovirus in head 3 
and neck squamous cell cancer can be enhanced by targeting the unfolded protein response 4 
(UPR) kinase, PERK. PERK inhibition by GSK2606414 increased reovirus efficacy in both 5 
2D and 3D models in vitro, while perturbing the normal host cell response to reovirus-6 
induced ER stress. UPR reporter constructs were used for live cell 3D spheroid imaging. 7 
Profiling of eIF2a-ATF4, IRE1a-XBP1 and ATF6 pathway activity revealed a context-8 
dependent increase in eIF2a-ATF4 signaling due to GSK2606414. GSK2606414 blocked 9 
eIF2a-ATF4 signaling due to the canonical ER stress agent thapsigargin. In the context of 10 
reovirus infection, GSK2606414 induced eIF2a-ATF4 signaling. Knockdown of eIF2a 11 
kinases PERK, GCN2 and PKR revealed eIF2a-ATF4 reporter activity was dependent on 12 
either PERK or GCN2. Knockdown of ATF4 abrogated the GSK2606414 induced increase in 13 
reovirus protein levels, confirming eIF2a-ATF signaling as key to the observed phenotype. 14 
Our work identifies a novel approach to enhance the efficacy and replication of reovirus in a 15 
therapeutic setting. 16 
 17 
  18 
 3
Introduction 1 
 2 
Reovirus type 3 Dearing (abbreviated hereafter as reovirus) is an immuno-oncolytic virus 3 
under active clinical development. It has been granted orphan drug status by the FDA for 4 
malignant glioma. It is a segmented, double-stranded RNA virus with 10 genome segments. 5 
Viral proteins provide self-sufficiency in relation to cellular entry via JAM1 and β1-integrins, 6 
endosomal escape allowing entry to the cytoplasm and viral genomic replication1,2. Reovirus 7 
is dependent on the translational machinery of infected cells for protein synthesis following 8 
release of viral RNA into the cytoplasm. 9 
 10 
Early studies indicated reovirus tumor selectivity was linked to inactivation of the PKR-11 
mediated anti-viral response driven by oncogenic transformation events 3,4. However, the 12 
role of PKR inactivation is debated within the field with evidence of reovirus sensitivity being 13 
PKR-independent 5,6. PKR forms part of the cellular integrated stress response (ISR). The 14 
ISR centres on the phosphorylation of eIF2a on Ser51 by the kinases Protein Kinase-R 15 
(PKR), PKR-like endoplasmic reticulum kinase (PERK), general control non-derepressible 2 16 
(GCN2) and Heme-regulated initiation factor 2 alpha kinase (HRI) 7. Phosphorylation 17 
prevents eIF2a forming the active GTP-bound state and ternary complex formation with Met-18 
tRNA and the 40S ribosome. This phosphorylation can be induced by anti-viral recognition of 19 
dsRNA by PKR, amino acid deprivation via GCN2, heme-deprivation via HRI or ER stress 20 
signaling via PERK,.  21 
 22 
PERK is a component of both the integrated stress response and the unfolded protein 23 
response (UPR). The UPR is a tripartite cellular response comprised of the ER 24 
transmembrane proteins PERK, IRE1a and ATF6 8,9. PERK phosphorylation of eIF2a 25 
decreases global protein translation while increasing translation of specific mRNA 26 
transcripts, such as ATF4, due to regulatory upstream open reading frames 10,11. IRE1a 27 
riboendonuclease activity splices an unconventional 26 nucleotide intron in XBP1 mRNA 28 
leading to translation of active spliced-XBP1 12. ATF6 activation is driven by trafficking to the 29 
Golgi where cleavage releases the soluble cytoplasmic transcription factor ATF6(N) 13. 30 
Through these three cytoplasmic transcription factors, UPR induction acts to resolve stress 31 
and restore normal protein homeostasis in the ER. 32 
 33 
While PKR has been shown to play a role in some but not all reovirus-permissive cells 5,14, 34 
modulation of global protein synthesis may still occur due to other kinases of the ISR, such 35 
as GCN2 and PERK. Studies have shown that reovirus induces ER stress and that this 36 
could be targeted as a strategy to increase reovirus efficacy. Early publications in this area 37 
 4
showed reovirus efficacy increased in combination with the proteasomal inhibitor bortezomib 1 
15,16
. More recently, BRAF-MEK inhibition sensitized melanoma to reovirus via increased ER 2 
stress 17. Basic research into reovirus biology indicates that despite a cytoplasmic lifecycle, 3 
reovirus exerts profound effects on the ER. Reovirus produces viral factories through 4 
reorganisation of cell membranes 18. Neo-organelle formation is driven by the non-structural 5 
proteins σNS and µNS 19 that act to remodel the ER forming viral inclusion structures. 6 
 7 
Given the ability of reovirus to induce ER stress, we hypothesised that compounds targeting 8 
the UPR may sensitize cancer to reovirus. We identified that the PERK inhibitor, 9 
GSK2606414, can sensitize head and neck cancer cells to reovirus. GSK2606414 enhanced 10 
both reovirus protein production and reovirus-positive areas modelled in 3D spheroids. 11 
Profiling of UPR pathways revealed this increase correlated with elevated signaling through 12 
eIF2a and ATF4.  This eIF2a-ATF4 signal was context dependent, only occurring due to the 13 
combination of reovirus and GSK2606414, not the canonical ER stress agent thapsigargin 14 
and GSK2606414. Use of shRNA against eIF2a kinases revealed PERK or GCN2 as the 15 
kinases responsible for increased eIF2a-ATF4 pathway activity. Knockdown by shRNA 16 
confirmed ATF4 was necessary for the GSK2606414 induced increase in reovirus protein 17 
levels. 18 
 19 
  20 
 5
Results 1 
 2 
Inhibition of PERK sensitizes HNSCC to reovirus 3 
The HPV-negative head and neck squamous cell carcinoma (HNSCC) cell lines HN5 4 
(tongue) and FaDu (hypopharynx) were used, both are characterised by TP53 mutations 5 
and high EGFR and HER2 levels 20. Survival experiments in 2D identified the PERK inhibitor 6 
GSK260414 sensitized FaDu and HN5 cells to reovirus across a range of viral MOIs (Fig. 7 
1A). Values shown are corrected for drug only toxicity. To assess drug-reovirus combination 8 
effects, Bliss independence analysis was carried out (Fig. 1B). Greater than expected cell kill 9 
was observed when single agent activity was compared to cell kill in combination. Reovirus 10 
MOIs of 20 and 75 were selected for FaDu and HN5 cells, respectively, due to these doses 11 
falling at the mid-point where combination efficacy was observed. These were used for all 12 
subsequent 2D and 3D assays. 13 
 14 
The ability of GSK2606414 to increase the efficacy of reovirus was assessed in 3D tumor 15 
spheroids. 3D models were used to augment 2D assays as 3D models are both a more 16 
clinically relevant method to model stress and were viewed as an approach to modelling the 17 
area of viral infection. Fluorescent ubiquitination cell cycle indicator-expressing 21 FaDu and 18 
HN5 cells were used to allow a more accurate assessment of spheroid area than brightfield 19 
images alone. Representative images after 7 days of GSK2606414 and reovirus infection 20 
are shown (Fig. 1C). Spheroids were imaged over 11 days after the addition of GSK2606414 21 
and reovirus. Automated image quantification of spheroid area based on fluorescence from 22 
multiple experiments is shown (Fig. 1D). GSK2606414 enhanced the efficacy of reovirus as 23 
measured by a reduction in spheroid area. Bliss independence analysis showed greater than 24 
expected reduction in volume due to combination treatment compared to single agents alone 25 
(Fig 1E). Efficacy in vivo was confirmed using both Tet-inducible PERK shRNA (shPERK) 26 
knockdown (Fig. 1F) and GSK2606414 in combination with reovirus (Fig 1G). Tumour 27 
volume reduction by reovirus was significantly higher in the shPERK group compared to 28 
scrambled knockdown (shSCR) control, and in combination with GSK2606414. Validation of 29 
PERK knockdown in vivo, efficacy of PERK knockdown in combination with reovirus in vitro, 30 
and in vivo curves in mm3 are shown in supplementary figure S1. 31 
 32 
GSK2606414 but not PERK knockdown increases reovirus protein levels in vitro and 33 
in vivo 34 
 35 
After confirming increased reovirus efficacy in combination with GSK2606414, we 36 
investigated the impact of GSK2606414 on reovirus replication. Reovirus capsid protein 37 
 6
levels were assessed in 2D culture by western blot (Fig. 2A), and reovirus particle 1 
production by TCID50 (Fig. 2B). GSK2606414 increased the levels of capsid proteins σ3 2 
and µ1C (Fig. 2A). GSK2606414 also increased viable reovirus particle production by 3 
TCID50, although this result was not statistically significant. It can be stated that viable 4 
reovirus particle production remains, at a minimum, undiminished despite decreasing cell 5 
viability in combination with GSK2606414. 6 
 7 
To probe the effects of GSK2606414 in comparison to PERK knockdown, we used 3D 8 
tumour spheroids to model the area of reovirus infection. Tumors at the end of in vivo 9 
experiments in figure 1F and 1G were also assessed for reovirus by IHF. Spheroids were 10 
treated with GSK2606414 and reovirus concurrently. After 96 h spheroids were formalin-11 
fixed, paraffin embedded and sectioned. Sections were stained for σ3 and µ1C by 12 
fluorescence-based immunohistochemistry (IHF) and confocal images quantified by 13 
automated image analysis. An overview of the image analysis pipeline is shown (Fig. 2C). 14 
Image segmentation was restricted to the peripheral edge of spheroid corresponding to a 15 
depth of 25 µm. This approach was taken due to localisation of the majority of reovirus 16 
infection to the spheroid periphery. 3D spheroid sections indicated GSK2606414 enhanced 17 
the area that stained positive for reovirus infection as measured by µ1C (Fig. 2D) and σ3 18 
(Fig. 2E). This could be attributed to an increase in the total number of infected cells due to 19 
GSK2606414, or an increase in reovirus capsid levels in cells at an early stage in infection 20 
compared to reovirus only conditions. Tet inducible knockdown was used as described for 21 
figure 1. PERK knockdown by 96 h pre-treatment with doxycycline to induce scrambled or 22 
PERK shRNA did not alter the percentage area positive for reovirus in 3D spheroids (Fig 23 
2E). Quantification of reovirus-positive areas at day 18 and day 20, respectively, from 24 
GSK2606414 or PERK knockdown in vivo experiments showed an increase due to 25 
GSK2606414 but not PERK knockdown, similar to observations in vitro (Fig 2F). These 26 
analyses indicated that while both PERK knockdown and GSK2606414 enhance tumor 27 
control by reovirus, only GSK2606414 quantifiably increased reovirus protein levels. 28 
 29 
GSK2606414 alters ER chaperone composition in response to reovirus 30 
 31 
Reovirus has previously been shown to increase levels of ER-resident chaperones, such as 32 
GRP78 and PDI 16. We sought to assess how GSK2606414 may modulate alterations in ER 33 
chaperone levels due to reovirus infection using the same 3D tumor spheroid approach used 34 
to model reovirus infection in vitro (Figure 3). As in figure 2, spheroids were treated with 35 
reovirus and GSK2606414 for 96 h before FFPE processing, sectioning and IHF imaging by 36 
 7
confocal microscopy. Automated image quantification was used to quantify areas of high 1 
chaperone expression as outlined for Figure 2C-E. This was isolated to the spheroid 2 
periphery as described previously for reovirus infection. In addition, the core of HN5 3 
spheroids displayed high levels of ER chaperones, peripheral quantification excluded 4 
changes in this core region not directly linked to reovirus infection (shown in image inset in 5 
Fig. 3A). 6 
 7 
Representative images are shown for the chaperone GRP78 (Fig. 3A), the ER retention 8 
motif KDEL (Fig. 3B) and the chaperone protein disulphide isomerase (PDI) (Fig 3C). 9 
GRP78 levels significantly increased following reovirus infection in both cell lines (Fig. 3D). 10 
GSK2606414 inhibited GRP78 induction at the edge of spheroids in both cell lines across all 11 
doses tested. The ER retention motif, KDEL, was stained to quantify global ER-resident 12 
protein levels (Fig. 3E). Reovirus induced an increase in global ER-resident proteins 13 
measured by KDEL-high areas that was further increased in combination with GSK2606414. 14 
Similar to KDEL, PDI high levels increased due to reovirus infection and were further 15 
increased by GSK2606414 addition (Fig. 3F). When comparing reovirus capsid staining 16 
patterns in Figure 2 to GRP78, KDEL and PDI staining, a degree of co-localisation was only 17 
apparent for PDI and capsid proteins in HN5 cells. Staining of GRP78 and KDEL, particularly 18 
in FaDu spheroids, was diffuse relative to highly discrete reovirus capsid positive areas. This 19 
indicates that stress induced by reovirus may be due to a combination of a bystander effect 20 
or also occurs at early stages of infection where capsid proteins are not yet detectable. 21 
 22 
Analyses mirroring spheroid data were performed on in vivo samples from end of experiment 23 
at day 18 and day 20 (supplementary figure S2). GSK2606414 in combination with reovirus 24 
in vivo strongly mirrored the increase in PDI observed in spheroids, with decreased GRP78 25 
less clear. PERK knockdown did not alter PDI levels due to reovirus, but increased GRP78 26 
alone at an earlier day 12 timepoint, or at day 20 in reovirus-infected areas. These data 27 
indicate both PERK knockdown and GSK2606414 can aggravate/alter the ER stress 28 
response to reovirus but the resulting profiles, as measured by the GRP78 and the redox 29 
chaperone PDI, are clearly divergent. 30 
 31 
GSK2606414 reduces signaling through XBP1 and ATF6 while increasing signaling 32 
via eIF2a-ATF4 33 
 34 
To understand what may be behind this perturbation of ER chaperones, we generated 35 
reporter constructs to investigate the three UPR signaling pathways responsible for 36 
regulating chaperone levels. An IRE1a endonuclease reporter contained the 26nt intron from 37 
 8
XBP1 in front of GFP. Splicing and removal of this intron, as is the case with XBP1 to 1 
spliced-XBP1, placed GFP in frame (IRE1alpha endonuclease reporter). Downstream of 2 
PERK and eIF2a, the 5’ upstream regulatory sequence of ATF4 was cloned in front of the 3 
start codon of mCherry (ATF4 promoter). Multiple repeats of the previously published ATF6 4 
transcription factor binding site 22 were cloned in front of mCherry (ATF6 reporter). All three 5 
are illustrated (Fig. 4A). The canonical ER stress-inducing agent, thapsigargin, was used to 6 
validate UPR reporter signaling in combination with GSK2606414 (Fig. 4B). Activation of all 7 
UPR reporters by thapsigargin was observed, except for IRE1 reporter activity in FaDu cells. 8 
Inhibition of thapsigargin-induced ATF4 reporter levels was clearly observed for 9 
GSK2606414, with compensatory increases in other UPR signal pathways (except IRE1 in 10 
FaDu cells). 11 
 12 
After reporter validation, ATF4, IRE1 and ATF6 reporter levels were imaged after 72h of 13 
reovirus infection and GSK2606414 treatment. Representative images are shown (Fig. 4C). 14 
Automated image quantification was used to determine reporter intensity across multiple 15 
independent experiments (Fig. 4D). No activation of the three arms of the UPR was 16 
observed due to reovirus in FaDu spheroids, while ATF6 and ATF4 activity was observed in 17 
HN5 spheroids. Though some degree of activation of ATF4 by reovirus was observed in 18 
later experiments (see Figure 5B-E). The most pronounced difference was an increase in 19 
ATF4 reporter levels due to GSK2606414 alone. This was highly pronounced in FaDu cells. 20 
ATF4 reporter levels increased further due to the combination of reovirus and GSK2606414 21 
in HN5 cells alone. To validate signaling upstream from ATF4, levels of pSer51 eIF2a were 22 
determined from 2D cell lysates by western blot (Fig. 4E). Densitometry from at least three 23 
independent blots is also shown (Fig. 4F). The pattern of pSer51 eIF2a was similar to that 24 
observed with the ATF4 reporter. These data indicated that signaling through eIF2a-ATF4 25 
appeared to be the main mechanistic change in UPR signaling during exposure to 26 
GSK2606414 and reovirus infection. 27 
 28 
 29 
Increased reovirus protein levels due to GSK2606414 are ATF4-dependent and due to 30 
increased signaling via PERK and GCN2 31 
 32 
In the comparison between thapsigargin and reovirus in Figure 4, we noted that the effect of 33 
GSK2606414 was context-dependent. Thapsigargin is a much stronger activator of UPR 34 
signaling than reovirus, In this context, GSK2606414 strongly inhibits ATF4 protomer 35 
activity. However, in the thapsigargin experiment (Fig. 4B), as well as with reovirus (Fig. 4C) 36 
we noted GSK2606414 alone caused an increase in ATF4 reporter signaling. Western blot 37 
 9
data (Fig. 4F) indicated that upstream pSer51 eIF2a levels correlated to ATF4 reporter 1 
levels. Based on previous data relating to reovirus and the integrated stress response 23, we 2 
believed that this may be responsible for the increase in reovirus protein production and 3 
infection. To help elucidate the mechanism behind this, doxycycline-inducible shRNA 4 
against the integrated stress response eIF2a kinases, PERK, GCN2 and PKR were used 5 
(shRNA validation Fig. 5A). 6 
 7 
The ATF4 reporter was combined with scrambled, PERK, GCN2 or PKR shRNA and the 8 
experiments of figure 4 were repeated. Knockdown of each eIF2a kinase was used to 9 
determine the source of ATF4 reporter activity (Fig. 5B,C). All 4 shRNA variants were tested 10 
in the absence of doxycycline (black circles) and shown to have similar results to earlier non-11 
shRNA cell lines in figure 4. Induction of scrambled shRNA with doxycycline (blue squares) 12 
was shown to have no effect on ATF4 reporter activity due to GSK2606414 and/or reovirus 13 
compared to no doxycycline control conditions. Doxycycline-induced knockdown of PERK 14 
reduced ATF4 reporter activity in all conditions in FaDu cells. This was most pronounced in 15 
GSK2606414 treatment conditions. No reduction was observed in HN5 cells. Doxycycline-16 
induced knockdown of GCN2 was seen to reduce ATF4 reporter activity in all conditions in 17 
HN5 cells. While a small decrease was seen in FaDu cells, this was not statistically 18 
significant. Doxycycline-induced knockdown of PKR significantly reduced the ATF4 reporter 19 
signal in HN5 cells treated with the combination of GSK2606414 and reovirus. 20 
 21 
In the context of previous comparative data between PERK knockdown and GSK2606414 22 
(Fig. 2, Supplementary Fig. S2), it is clear that PERK knockdown alone does not increase 23 
ATF4 reporter activity in either FaDu or HN5 cells (Fig. 5B,C). This was a mechanistically 24 
distinct difference between PERK knockdown and GSK26006414 and potentially the reason 25 
behind the disparate effects observed when assessing reovirus levels in figure 2. 26 
 27 
To test if increasing pSer51 eIF2a levels (Fig. 4E,F) and ATF4 reporter levels (Fig. 4D; Fig. 28 
5B-E) due to GSK2606414 was the key driver behind increased reovirus protein levels, 29 
doxycycline-induced knockdown of ATF4 was used (ATF4sh). Knockdown was validated at 30 
the mRNA level by PCR (Fig. 5D). Transcript variant 2 was detectable in both cells, with 31 
mRNA levels significantly reduced with doxycycline treatment. ATF4sh blocked increased 32 
reovirus µ1C levels due to GSK2606414 (Fig. 5E). Unlike in combination with thapsigargin, 33 
in the context of reovirus infection, GSK2606414 can increase signaling through eIF2a-34 
ATF4. ATF4sh confirmed this signaling event as the reason behind increased reovirus 35 
protein replication due to GSK2606414. As an additional confirmation, we tested if the potent 36 
induction of ATF4 reporter activity observed in figure 4B by thapsigargin alone could also 37 
 10 
increase reovirus levels. This proved to be the case (Fig. 5F) suggesting conditions which 1 
enhance ATF4 activity have positive consequences for reovirus protein production.  2 
 3 
 4 
GSK2606414 increases GM-CSF secretion in combination with reovirus 5 
 6 
To assess the impact of GSK2606414 on reovirus-induced cytokine secretion, an array was 7 
used to profile alterations to cytokine secretion in vitro in HN5 cells (Fig 6A,B). This indicated 8 
changes to a number of cytokines. Most prominent were increased levels of GM-CSF and 9 
decreased levels of a number of T-cell chemoattractants such as CXCL9, 10 and 11 as well 10 
as decreased CCL5. However 11 
 12 
GM-CSF and CXCL10 findings were validated by ELISA in both FaDu and HN5 cells. This 13 
confirmed the increase of GM-CSF in combination with reovirus in HN5s (Fig 6C). FaDu 14 
cells did not appear to secrete GM-CSF under any conditions, in keeping with other data on 15 
radiation which also showed an absence of GM-CSF expression in FaDu cells 24. A 16 
decrease in reovirus induced CXCL10 secretion by GSK2606414 was observed for both 17 
FaDu and HN5 cells. It should be noted however that GSK2606414 reduced CXCL10, but 18 
the levels in the combination group was still substantially greater than untreated controls. 19 
These data indicate that GSK2606414 may aid dendritic cell infiltration and antigen 20 
presentation through GM-CSF, but potentially dampen T-cell chemotaxis through reduced 21 
levels of the CXCR3 ligands CXCL9-11.  22 
 23 
  24 
 11 
Discussion  1 
 2 
Previous publications have shown that inhibition of BRAF or MEK enhanced the efficacy of 3 
reovirus via a mechanism involving ER stress 17. We hypothesised that direct targeting of 4 
UPR signaling may present an opportunity to sensitize HNSCC to reovirus. This led us to 5 
identify the PERK inhibitor, GSK2606414, as increasing the efficacy of reovirus in HNSCC. 6 
 7 
We observed that GSK2606414 increases reovirus protein levels measured by western blot, 8 
as well as the area positive for infection in 3D spheroids and in vivo. Tripartite UPR signaling 9 
reporters were created to allow monitoring of the UPR in 3D. Initial validation with 10 
GSK2606414 and thapsigargin was as expected, with ATF4prom activity blocked by 11 
GSK2606414. This coincided with a compensatory increase in the IRE1a and ATF6 UPR 12 
pathways. Our original expectation was that reovirus would act much the same as 13 
thapsigargin. However, this was not the case, with clear differences in UPR signaling due to 14 
reovirus compared to thapsigargin. While GSK2606414 blocked canonical thapsigargin-15 
induced eIF2a-ATF4 signaling, single-agent GSK2606414 yielded an increase. This 16 
increase was maintained in FaDu cells and further enhanced in HN5 cells following co-17 
treatment with reovirus. The effect of GSK2606414 was, therefore, context-dependent. In a 18 
search of the literature, we were able to corroborate these findings. Single-agent 19 
GSK2606414 has been shown previously to increase pSer51 eIF2a 25, although this specific 20 
observation was not discussed in that study. To our knowledge, this is the first commentary 21 
on this observed phenotype in the literature.  22 
 23 
In vivo and in vitro data indicated PERK knockdown or GSK2606414 increased tumor 24 
control by reovirus, yet the profile of ER stress markers differed. PERK knockdown clearly 25 
increased GRP78 levels at day 12 in vivo, and increased GRP78 levels in reovirus-infected 26 
areas, as well as adjacent areas likely to be in the early stages of infection. Upregulation of 27 
GRP78 is a marker of UPR induction and elevated stress. This aggravated stress appears 28 
mechanistically different to GSK2606414. Yet either aggravation or perturbation of ER stress 29 
signaling by PERK knockdown or GSK260414, respectively, appear to share the same 30 
therapeutically beneficial outcome. PERK knockdown failed observably to increase reovirus 31 
levels as shown for GSK2606414. These data are in keeping with the identified ATF4-32 
dependent mechanism as PERK knockdown does not induce ATF4 reporter signaling. The 33 
precise contribution of these quantifiably increased reovirus metrics to efficacy is difficult to 34 
determine. It is logical to conclude that conditions whereby anti-tumor efficacy coincides with 35 
increased reovirus persistence is anticipated to be a more therapeutically beneficial 36 
scenario. 37 
 12 
 1 
Activation of the integrated stress response has been associated with a cellular environment 2 
supportive of reovirus replication 23. Isogenic pairs of murine embryonic fibroblasts (MEFs) 3 
rather than cancer cell lines were studied, but a possible role in therapeutic efficacy was not 4 
investigated. In that study, reovirus replication was not altered in PERK knockout MEFs but 5 
was reduced by ATF4 knockout. Our data in a therapeutic context agree with these findings. 6 
Increased eIF2a-ATF4 signaling activity due to GSK2606414 corresponded to increased 7 
reovirus protein levels with ATF4 knockdown abolishing this increase. 8 
 9 
To determine the mechanism behind the increase in eIF2a-ATF4 activity due to 10 
GSK2606414, shRNAs against the eIF2a kinases PERK, GCN2 and PKR were used in 11 
combination with an ATF4 reporter (Fig. 5B,C). In FaDu cells, ATF4 reporter activity 12 
triggered by GSK2606414 was PERK-dependent, whereas in HN5 cells enhanced reporter 13 
activity was GCN2-dependent across all conditions, with PKR contributing only when 14 
reovirus was combined with GSK2606414. PERK, GCN2 and PKR all form dimers upon 15 
activation 26-28. A recent publication has shown that PERK interacts with the actin regulator 16 
FLNA, independent of UPR signaling 29. In that study, PERK-null cells were reconstituted 17 
with PERK lacking the luminal domain. This clearly showed the ability of GSK2606414 to 18 
induce PERK dimerization independent of the luminal domain and without the need for 19 
thapsigargin treatment. The interaction of PERK-FLNA increased on treatment with 20 
GSK2606414, indicating that PERK dimerization and not just kinase activity is sufficient to 21 
drive this protein-protein interaction. It is plausible that in the context of reovirus infection, a 22 
similar mechanism of action may contribute to the phenotype we observe in this study. 23 
 24 
The initial discovery that PERK inhibitors stabilised dimerization was made in the context of 25 
a structural similarity to RAF inhibitor-driven kinase dimerization 30. Inhibitors of wild-type 26 
BRAF can drive activation of mutant RAS independently of kinase activity 31-33. RAF can 27 
form homodimers or heterodimers with drug binding inhibiting one subunit of the dimer but 28 
inducing transactivation of the other 33. In Lavoie et al, they concluded that PERK inhibition 29 
may result in transactivation of structurally similar GCN2, PKR or HRI, although eIF2a 30 
kinase heterodimers have not been reported in the literature. The PERK-dependent increase 31 
in ATF4 activity due to GSK2606414 observed in FaDu cells would be in keeping with such 32 
transactivation 30 and dimerization events 29. This suggests a mode of action where 33 
GSK2606414 in the context of reovirus infection enhances eIF2a-ATF4 signaling supporting 34 
enhanced viral protein production.  35 
 36 
 13 
The lack of PERK dependence in HN5 cells does not fit this model, but, due to the structural 1 
similarity of GCN2 to PERK, it is not inconceivable that some degree of off-target 2 
transactivation of GCN2 could be induced by GSK2606414 at the concentrations used. That 3 
this was not also observed in FaDu cells may be due to sub-optimal knockdown of GCN2 as 4 
a non-significant decrease in GSK2606414 conditions was observed. It has been shown that 5 
GSK2606414 has off-target inhibitory effects, notably on RIPK1 34 and cKIT 35. In 6 
experiments comparing RIPK1 inhibitors to GSK2606414 and thapsigargin (supplementary 7 
figure S3), increased reovirus protein levels due to GSK206414 did not appear to be linked 8 
to off-target RIPK1 inhibitory effects.  Knockdown data on PERK, GCN2 and ATF4 suggests 9 
that the effects observed in this study are isolated to UPR signaling alone. 10 
 11 
In conclusion, our study reveals GSK2606414 modulates UPR signaling in combination with 12 
reovirus in a fashion that is mechanistically different to the canonical ER stress-inducing 13 
agent thapsigargin. The context-dependent modulation of UPR signaling due to 14 
GSK2606414 allows increased translation of reovirus proteins in an ATF4-dependent 15 
manner. This can lead to an increase in the area positive for reovirus infection as modelled 16 
in 3D spheroids and in vivo. This suggests that future clinical translation should investigate 17 
the role of ER stress and in particular ATF4 in profiling susceptibility to reovirus. 18 
Combinations of reovirus and agents that enhance ER stress signaling through ATF4 should 19 
be considered for future clinical studies. 20 
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Materials and Methods 1 
 2 
Cell culture and compounds. FaDu and 293T cells were purchased from ATCC. LON-3 
LICR-HN5 cell lines from Professor Sue Eccles (ICR, London, UK). Cells were cultured in 4 
DMEM, 5% FBS, 1% (v/v) glutamine, and 0.5% (v/v) penicillin/streptomycin. STR profiling 5 
was carried out by Bio-Synthesis Inc. Mycoplasma testing used the e-Myco PCR kit (Intron 6 
Biotechnology). Experiments were carried out within 3 months of resuscitation. GSK2606414 7 
was obtained from MedKoo Biosciences (NC, USA). Doxycycline hyclate was obtained from 8 
Sigma Aldrich (Gillingham, UK). Reovirus type 3 Dearing (Reolysin/pelarorep) was kindly 9 
supplied by Oncolytics Biotech (Calgary, Canada). 10 
 11 
MTT viability assay. Cells were seeded in 96-well plates. After 24 h GSK2606414 and 12 
reovirus was added concurrently. Viability was determined at 72 hours by MTT assay. 13 
Absorbance at 550 nm was measured and viability normalized to control DMSO-treated 14 
cells. 15 
 16 
3D spheroid size imaging. Cells were plated in ultra-low attachment plates (Corning, 17 
#7007). Cells contained cell cycle tracker proteins as previously described 21,36 which were 18 
used to visualise spheroid area. Medium was refreshed every 48 h. At 96 h post-plating, 19 
GSK2606414 and reovirus were added. GSK2606414 was refreshed every 48 h after 20 
addition. Spheroids were imaged at a fixed exposure throughout the experiment on an 21 
EVOS FL microscope (ThermoFisher, UK). Spheroid area was quantified by automated 22 
image quantification of mCherry and AMCyan channels combined using Cell Profiler v3 23 
(Broad Institute, MA, USA). 24 
 25 
Immunoblotting. Cells were scraped in RIPA buffer (ThermoFisher) containing 2 mmol/L 26 
Na3VO4 and protease inhibitors. Supernatants were quantified by BCA assay (Pierce), 27 
separated by SDS-PAGE, transferred to PVDF membrane (ThermoFisher) and blocked in 28 
TBS with 5% non-fat dry milk and 0.1% Tween-20. Membranes were probed with the 29 
antibodies: pSer51 eIF2a #3398, PERK #5683, GCN2 #3202, PKR #12297, GAPDH #2118 30 
from Cell Signaling Technology (MA, USA); reovirus µ1C 10F6 and reovirus σ3 4F2 were 31 
from the Developmental Studies Hybridoma Bank (IA, USA); ATF4 ab184909 and Beta Actin 32 
ab8226 were from Abcam (Cambridge, UK). 33 
 34 
One-step viral growth TCID50 assay. Cells were plated in 24-well plates. After 24 h cells 35 
were infected with reovirus with or without GSK2606414. After 2 h media was removed and 36 
cells were washed once with PBS. Fresh reovirus free media with or without GSK2606414 37 
 15 
was added. Cells and supernatant were harvested and freeze-thawed three times. Resulting 1 
supernatants were titred by serial dilution on L929 cells as previously described 37. 2 
 3 
Immunofluorescence. Spheroids were rinsed in PBS before fixation in 10% neutral 4 
buffered formalin (NBF). Spheroids were embedded in histogel before paraffin-embedding 5 
and sectioning. In vivo tumors were fixed in NBF before paraffin-embedding and sectioning. 6 
Heat-induced antigen retrieval was performed using pH6 sodium citrate buffer. Tissue was 7 
blocked using 5 % BSA before incubation with the following antibodies: PERK #5683, 8 
GRP78 #3177 and PDI #3501 were from Cell Signaling Technologies (MA,USA); KDEL 9 
10C3 was from Enzo (Exeter, UK); reovirus µ1C 10F6 and reovirus σ3 4F2 were from the 10 
Developmental Studies Hybridoma Bank (IA, USA). Alexafluor 488, 546 and 647 conjugates 11 
of anti-rabbit IgG H+L, anti-mouse IgG H+L, anti-mouse IgG2a and anti-mouse IgG2b were 12 
from ThermoFisher (UK). Spheroid sections were imaged on a Zeiss 710 confocal (Jena, 13 
Germany) with quantification using Cell Profiler v3. Exposure settings were based on the 14 
minimum possible which still allowed robust spheroid identification for segmentation. 15 
Controls were compared during exposure setup to ensure similar intensities across 16 
experiments. Stained sections from in vivo tumor samples were imaged on a Perkin Elmer 17 
Vectra 3.0 with spectral unmixing of images performed using Perkin Elmer Inform software. 18 
Image quantification performed using Cell Profiler v3 as described in results. 19 
 20 
Cytokine Profiling. Media 48 h after treatment with reovirus and GSK2606414 was 21 
collected and centrifuged to remove cells or debris. Initial profiling used the proteome profiler 22 
human XL cytokine array kit from R&D systems (MN, USA). Array results were quantified by 23 
densitometry using ImageJ (FIJI v2). Validation of array findings used the human 24 
CXCL10/IP-10 Duoset and human GM-CSF Duoset ELISA kits from R&D systems. 25 
 26 
UPR reporter constructs and high-content Imaging. Reporter constructs were cloned into 27 
the lentivirus pHRSIN (kindly provided by Professor Greg Towers, UCL, London). Primers 28 
are listed in supplementary Table S1. The region encoding the 26nt intron from XBP1 29 
excised by IRE1a riboendonuclease activity was incorporated by PCR in front of eGFPFLAG 30 
and inserted between SFFV and WPRE elements (LV-IRE1endo). 1800 bp upstream of the 31 
ATF4 start codon was amplified from genomic DNA by PCR, with a second PCR referred to 32 
as extended primers adding overlap assembly regions at the 5’ end for pHRSIN and the 3’ 33 
end for mCherry. mCherry was amplified by PCR using an initial PCR including a previously 34 
cloned C-terminal MYC tag, followed by a second PCR to add a 3’ overlap assembly region 35 
with pHRSIN. This was assembled into pHRSIN using NEBuilder (NEB, USA) resulting in 36 
mCherry with the 5’ 1800bp genomic sequence of ATF4 and a 3’ WPRE element from 37 
 16 
pHRSIN (LV-ATF4prom). Using the previously published ATF6 binding site 22 5-repeats of 1 
the binding site (addgene ID 11976) were inserted in front of eGFP-WPRE (LV-ATF6bind). 2 
Lentiviral reporter constructs were packaged using MD2.G and psPAX2 in 293T cells using 3 
lipofectamine 2000. Supernatants containing polybrene were used to infect cell lines with 4 
reporter constructs individually and selected using puromycin or blasticidin. Reporter 5 
expression was measured using a Celigo S high-content imaging system from Nexcelom 6 
Bioscience (MA, USA). Spheroid recognition and average reporter intensity was quantified 7 
using Cell Profiler v3. 8 
 9 
Tet-pLKO-puro shRNA. Short hairpin RNA sequences for scrambled, PERK, GCN2, PKR 10 
and ATF4 were cloned into the Tet-pLKO-puro system 38. Target sequences: scrambled, 11 
GACAAGTTAAGAACCGCGA; PERK, CCGTGAAAGCATGGAAACA; GCN2, 12 
TGGCTAAGCAGGAACGTTT; PKR, GGGCTAATTCTTGCTGAAC; ATF4, 13 
TGCTTACGTTGCCATGATC. Knockdown was validated after 96 h in 400 µg/mL 14 
doxycycline with fresh doxycycline added at 48 h. In all experiments, doxycycline was 15 
refreshed every 48 h until the end of the experiment. GSK2606414 and reovirus addition 16 
took place after 96 h of pre-treatment with doxycycline. Validation by western blot, except for 17 
ATF4 which was by PCR. For PCR validation, RNA was prepped using an RNeasy Plus kit 18 
(Qiagen), converted to cDNA using Protoscript II (NEB), with PCR performed using GoTaq 19 
DNA polymerase (Promega). ATF4 transcript variant 1 and 2 primers are listed in 20 
supplementary table 2. In studies combining Tet-pLKO-puro shRNA with LV-ATF4prom, 21 
puromycin and blasticidin were used sequentially for selection of positively infected cells. 22 
Imaging and quantitation as outlined previously for UPR reporters. 23 
 24 
In vivo. All experiments were approved by the Institutional Ethics Review 25 
Board. Female NOD scid gamma (NSG) mice were obtained from Charles River, 2 million 26 
HN5 cells were implanted subcutaneously. HN5 cells were parental, or contained Tet-pLKO-27 
puro SCR shRNA or PERK-targeting shRNA. Scrambled shRNA groups contained n=6 28 
mice, PERK shRNA n=5. Doxycycline in 5% dextrose was given once daily by oral gavage 29 
for the duration of the experiment to all groups. Reovirus was injected intratumorally as 30 
1x105 plaque forming units in a volume of 30 µL of PBS on day zero. Sham injection 31 
consisted of PBS only. GSK2606414 50 mg/kg or vehicle was administered via oral gavage 32 
once per day using a 5 days on, 2 days off schedule commencing on day zero. Vehicle was 33 
0.5% hydroxypropyl methylcellulose and 0.1% Tween 80. Reovirus was injected 34 
intratumorally as 1x105 plaque forming units in a volume of 30 µL of PBS on day zero, and 35 
 17 
1x107 in 30 µL of PBS on day nine. Sham injection consisted of PBS only. Tumor diameters 1 
were measured by vernier calipers and volume calculated as (width x width x length)/2.  2 
 3 
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Figure 1. GSK2606414 sensitizes HNSCC to reovirus. (A) Cell viability of FaDu and HN5 HNSCC 1 
cell lines was determined at 72h by MTT assay. GSK2606414 and reovirus were added concurrently. 2 
(B) Observed cell kill vs expected cell kill for MTT assays was determined by Bliss independence 3 
analysis. Expected cell kill is calculated on the assumption single agents are non-interacting. Positive 4 
∆E corresponds to greater observed kill than expected, negative ∆E less than expected. Full details 5 
outlined in methods. (C, D) FaDu and HN5 HNSCC cell lines were plated in low attachment U-bottom 6 
plates to form 3D tumour spheroids expressing G1-mCherry and G2-AMCyan cell cycle trackers. 7 
Spheroids were treated with GSK2606414 and reovirus concurrently. Spheroids were imaged using 8 
cell cycle tracker fluorescence at the indicated time points. Area relative to control was calculated by 9 
automated image quantification. (E) Observed reduction vs expected reduction for 3D spheroid areas 10 
was determined by Bliss independence analysis as in panel B. (F) Increased efficacy of reovirus in 11 
combination with loss of PERK was determined in vivo by Tet-inducible shRNA. HN5 cells stably 12 
expressing lentiviral Tet-pLKO-puro were injected subcutaneously into NSG mice. HN5 cells 13 
contained either scrambled shRNA (SCRsh) or PERK targeting shRNA (PERKsh). All mice received 14 
50 mg/Kg doxycycline daily by gavage with reovirus delivered by intra-tumoral injection at day zero. 15 
Tumor volumes expressed relative to start volume. For validation of knockdown see supplementary 16 
figure S1. (G) Increased efficacy of reovirus in combination with GSK2606414 was determined in vivo 17 
in HN5 cells injected subcutaneously into NSG mice. Mice received 50 mg/kg GSK2606414 on days 18 
0-4, 7-11,14-18 with two injections of reovirus on day zero and day 9. A and D, data ±SEM of at least 19 
three independent experiments. Bliss independence analysis in B and E shown with 95% confidence 20 
intervals. In vivo statistical analysis shown between groups in F and G by unpaired t-test *P < 0.05 of 21 
area under curve comparison for individual tumors. 22 
 23 
Figure 2. GSK2606414 increases reovirus infection in 2D and modelled in 3D tumor spheroids. 24 
(A) Lysates from 2D cell culture at the time points indicated after treatment were probed by western 25 
blot for the reovirus capsid proteins µ1C and σ3. (B) Viable replicating reovirus particle production 26 
from media and cells combined from 2D culture was quantified by TCID50 assay. (C, D, E) HNSCC 27 
cell lines were plated in low attachment U-bottom plates to form spheroids and treated as in Figure 1. 28 
96 h after treatment spheroids were collected, formalin-fixed, paraffin embedded and sectioned. 29 
Sections were stained for reovirus µ1C and σ3 by IHF to quantify the area positive for reovirus 30 
infection. Confocal images were quantified by automated image quantification of infected areas as 31 
illustrated. 20x field of view shown corresponds to 415 x 415 µm. Due to reovirus only accessing and 32 
infecting the peripheral edge of the spheroid, quantification was restricted to a depth of 25 µM. 33 
Further details on this rationale are outlined in the results section. (E) 3D spheroids containing SCR or 34 
PERK shRNA were treated with doxycycline for 96h before infection with reovirus. After a further 96 h 35 
in doxycycline, spheroids were collected and stained for reovirus µ1C as described for C-D. (F) FFPE 36 
tumors from end of experiment from figure 1F and 1G were sectioned and stained for reovirus µ1C by 37 
IHF. Slides were imaged on a Perkin Elmer Vectra 3 and the percentage area positive for reovirus 38 
quantified using cell profiler software averaged from two sections. Reovirus-positive areas are 39 
expressed as fold change relative to reovirus alone for GSK2606414, or scrambled shRNA for PERK 40 
 23 
shRNA knockdown. Spheroid datapoints represent the average of 4-8 spheroids within a single 1 
independent experiment. All figure data ±SEM, statistical analysis by unpaired t-test *P < 0.05. 2 
 3 
Figure 3. GSK2606414 inhibits reovirus induced GRP78 while increasing PDI and overall ER 4 
resident KDEL levels. FaDu and HN5 HNSCC 3D tumor spheroids were treated with GSK2606414 5 
and reovirus for 96h before spheroids were formalin-fixed, paraffin embedded and sectioned. 6 
Sections were stained by IHF for (A) GRP78, (B) KDEL and (C) PDI. 20x field of view shown 7 
corresponds to 415 x 415 µm. Confocal images were quantified for areas of high expression, 8 
restricted to the peripheral 25 µM as previously outlined in figure 2. Quantification for both FaDu and 9 
HN5 cells shown for (D) GRP78, (E) KDEL and (F) PDI. Each point represents an independent 10 
experiment where each experiment is an average of 4-8 spheroids. Data ±SEM with statistical 11 
analysis by unpaired t-test *P < 0.05. 12 
 13 
Figure 4. GSK2606414 increases UPR signalling through eIF2a-ATF4 while decreasing 14 
signalling through IRE1alpha and ATF6. (A) Illustration of tripartite UPR reporter design for live cell 15 
imaging of: IRE1a splicing of XBP1 intron sequence; ATF4 translation downstream of eIF2a; and 16 
activity of the ATF6 consensus DNA binding sequence. (B) 3D tumor spheroids containing reporter 17 
constructs were treated with 100 nM thapsigargin, 5 µM GSK2606414 and imaged at 72 h to profile 18 
lentiviral UPR reporter constructs. To aid clarity, greyscale images are presented using the pseudo-19 
colour scale shown. (C) 3D tumor spheroids containing reporter constructs were treated with reovirus 20 
and GSK2606414 and imaged at 72h. (D) Automated image analysis was used to identify spheroids 21 
and calculate average reporter intensity. Each data point represents an independent experiment, 22 
each containing the average of at least 4 spheroids. (E) 2D cell lysates were collected after 48 h 23 
treatment of cells with reovirus and GSK2606414. Lysates were probed for pSer51 EIF2a. (F) 24 
Densitometry quantification of pSer51 eIF2a from western blots of three independent experiments. 25 
Data is corrected for loading and normalised to control. Data ±SEM of a minimum of three 26 
independent experiments with statistical analysis by unpaired t-test *P < 0.05. 27 
 28 
Figure 5. In the context of Reovirus infection, GSK2606414 promotes eIF2a-ATF4 signalling via 29 
PERK or GCN2 with increased viral protein levels ATF4-dependent. (A) Western blot of cell 30 
lysates from 2D culture validating Tet-pLKO shRNA knockdown of PERK, GCN2 and PKR after 96 h 31 
of doxycycline treatment. (B-C) FaDu and HN5 cells were co-infected with ATF4-mCherry reporter in 32 
combination with Tet-pLKO SCR, PERK, GCN2 or PKR targeting shRNA. Spheroids were treated for 33 
96h with doxycycline before treatment with GSK2606414 and reovirus. Reporter expression was 34 
imaged at 72h matching the timepoint used in figure 4. Control values (black circles) are for parental 35 
Tet-pLKO cell lines in the absence of doxycycline knockdown, shRNA values (blue squares) 36 
correspond to doxycycline induced shRNA expression and knockdown. (D) FaDu and HN5 cells were 37 
infected with Tet-pLKO inducible shRNA targeting ATF4 or scrambled control. ATF4 transcript variant 38 
2 but not variant 1 was present in both cell lines. Knockdown after 96 h of doxycycline treatment was 39 
confirmed by PCR. Quantitation of PCR band intensity from three independent experiments 40 
 24 
expressed relative to SCR control for each cell line. (E) After 96 h of pre-treatment with doxycycline to 1 
establish ATF4 knockdown, cells were exposed to reovirus and GSK2606414 for 48 h before analysis 2 
of reovirus µ1C protein levels by western blot. (F) Cell were treated with DMSO control, GSK2606414 3 
or thapsigargin in combination with reovirus and analyzed at 48 h for µ1C protein levels by western 4 
blot. Data ±SEM of a minimum of three independent experiments with statistical analysis by unpaired 5 
t-test *P < 0.05. 6 
 7 
Figure 6. GSK2606414 modulates cytokine production in response to reovirus, increasing GM-8 
CSF levels. (A, B) A human cytokine array was used to assess cytokine secretion in vitro in response 9 
to reovirus in combination with GSK2606414 after 48 h. Only cytokines where changes were 10 
observed are shown, with levels quantified and displayed also by heatmap. (C, D) Findings for GM-11 
CSF and CXCL10 were validated by ELISA using media at 48 h. Data ±SEM of a minimum of three 12 
independent experiments with statistical analysis by unpaired t-test *P < 0.05. 13 
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